Science Corporation Implants PRIMA Vision Chip in Stargardt Patient

Overview

Neural engineering firm Science Corporation has achieved a significant medical milestone by successfully placing its PRIMA vision-restoring implant into a patient diagnosed with Stargardt disease. The procedure, executed at the Sydney Eye Hospital in Australia, marks a critical expansion for the technology, which had previously targeted geographic atrophy caused by advanced age-related macular degeneration.

Stargardt disease is a hereditary condition that gradually destroys central vision by degenerating the light-sensitive cells in the outer retina while frequently leaving the inner neural pathways intact. Approximately 150,000 individuals globally grapple with this progressive, currently incurable form of vision loss.

Engineering the Neural-Visual Interface

The PRIMA system operates by leveraging the fundamental principle that biological vision is essentially electrical activity traveling along the optic nerve. During a brief, hour-long surgical procedure, a microscopic chip measuring two by two millimeters is positioned subretinally in the back of the eye, effectively substituting for dead photoreceptor cells.

Patients outfitted with the implant wear specialized glasses equipped with outward-facing cameras. These glasses project environmental imagery directly onto the subretinal chip via infrared light beams. The implant converts these light patterns into electrical impulses that stimulate surviving retinal cells, transmitting signals up the optic nerve to the visual cortex.

While the current iteration provides a localized, high-contrast, black-and-white patch of vision comparable to looking through a straw, clinical outcomes have proven encouraging. Following rehabilitation, the trial participant successfully identified letters and read full words during initial evaluation sessions.

Scaling the Technology and Future Horizons

Founded by former Neuralink executive Max Hodak, Science Corporation views retinal prosthetics as part of a broader spectrum of brain-computer interfaces (BCIs). Unlike surface-level or penetrating cortical approaches, the company's overarching portfolio spans diverse neurological applications, including neural activity monitoring for brain tumors, stroke rehabilitation, and neurodegenerative disorders.

Engineering teams are already iterating on the next generation of the subretinal implant. Future hardware updates aim to widen the field of view by accommodating the natural curvature of the eyeball and shrinking electrode footprints to achieve native-level visual acuity. As clinical trials progress, these developments promise to transform the standard of care for degenerative neurological and sensory conditions.